CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019
Gottfried Fischer, MD, Medical Universityof Vienna, presenting data on AlloSeq cfDNA Milena Vrana, Head of HLA department, Institute of Hematology and Blood Transfusion, Prague, Czech Republicpresenting data on QTYPE
Donor-Derived Cell-Free DNA Correlates With Rejection in Kidney Allografts
TARGETED Gene Sequencing Following Enrichment using Capture Probes: The Next Generation of Genetic Matching in Transplantation
Donor-Derived Cell-Free DNA Levels Are Independent Of Degree Of Mismatch and Donor Type
AlloSeq CfDNA, A Donor-Derived Cell-Free DNA Measurement Solution For On-Site Monitoring of Solid Organ Transplants
QTYPE, the Fastest Method for HLA Genotyping by Real-Time PCR
“Transplant is global and
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company’s participation at EFI. These forward-looking statements are based upon information that is currently available to
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.